Literature DB >> 19949052

Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells.

M Juliana McElrath1, Lamar Ballweber, Andrew Terker, Allison Kreger, Polachai Sakchalathorn, Barry Robinson, Michael Fialkow, Gretchen Lentz, Florian Hladik.   

Abstract

Vaginally applied microbicides hold promise as a strategy to prevent sexual HIV transmission. Several nonspecific microbicides, including the polyanion cellulose sulfate, have been evaluated in large-scale clinical trials but have failed to show significant efficacy. These findings have prompted a renewed search for preclinical testing systems that can predict negative outcomes of microbicide trials. Moreover, the pipeline of potential topical microbicides has been expanded to include antiretroviral agents, such as reverse transcriptase, fusion, and integrase inhibitors. Using a novel ex vivo model of vaginal HIV-1 infection, we compared the prophylactic potentials of two forms of the fusion inhibitor T-20, the CCR5 antagonist TAK-778, the integrase inhibitor 118-D-24, and cellulose sulfate (Ushercell). The T-20 peptide with free N- and C-terminal amino acids was the most efficacious compound, causing significantly greater inhibition of viral genomic integration in intraepithelial vaginal leukocytes, measured by an optimized real-time PCR assay, than the more water-soluble N-acetylated T-20 peptide (Fuzeon) (50% inhibitory concentration [IC50], 0.153 microM versus 51.2 microM [0.687 ng/ml versus 230 ng/ml]; P<0.0001). In contrast, no significant difference in IC50s was noted in peripheral blood cells (IC50, 13.58 microM versus 7.57 microM [61 ng/ml versus 34 ng/ml]; P=0.0614). Cellulose sulfate was the least effective of all the compounds tested (IC50, 1.8 microg/ml). These results highlight the merit of our model for screening the mucosal efficacies of novel microbicides and their formulations and potentially rank ordering candidates for clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19949052      PMCID: PMC2812173          DOI: 10.1128/AAC.00891-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.

Authors:  Peter D Kwong; Michael L Doyle; David J Casper; Claudia Cicala; Stephanie A Leavitt; Shahzad Majeed; Tavis D Steenbeke; Miro Venturi; Irwin Chaiken; Michael Fung; Hermann Katinger; Paul W I H Parren; James Robinson; Donald Van Ryk; Liping Wang; Dennis R Burton; Ernesto Freire; Richard Wyatt; Joseph Sodroski; Wayne A Hendrickson; James Arthos
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

Review 2.  Novel therapies based on mechanisms of HIV-1 cell entry.

Authors:  J Michael Kilby; Joseph J Eron
Journal:  N Engl J Med       Date:  2003-05-29       Impact factor: 91.245

3.  Langerhans' cells and lymphocyte subsets in the female genital tract.

Authors:  J N Edwards; H B Morris
Journal:  Br J Obstet Gynaecol       Date:  1985-09

4.  Divalent cation-mediated epithelial union with connective tissue.

Authors:  L J Scaletta; D K MacCallum
Journal:  Exp Cell Res       Date:  1971-10       Impact factor: 3.905

5.  Azido-containing aryl beta-diketo acid HIV-1 integrase inhibitors.

Authors:  Xuechun Zhang; Godwin C G Pais; Evguenia S Svarovskaia; Christophe Marchand; Allison A Johnson; Rajeshri G Karki; Marc C Nicklaus; Vinay K Pathak; Yves Pommier; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2003-03-24       Impact factor: 2.823

6.  Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

Authors:  Michael M Lederman; Ronald S Veazey; Robin Offord; Donald E Mosier; Jason Dufour; Megan Mefford; Michael Piatak; Jeffrey D Lifson; Janelle R Salkowitz; Benigno Rodriguez; Andrew Blauvelt; Oliver Hartley
Journal:  Science       Date:  2004-10-15       Impact factor: 47.728

7.  Calcium ions are required for cell fusion mediated by the CD4-human immunodeficiency virus type 1 envelope glycoprotein interaction.

Authors:  D S Dimitrov; C C Broder; E A Berger; R Blumenthal
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

8.  Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus.

Authors:  Audrey Brussel; Pierre Sonigo
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.

Authors:  Evguenia S Svarovskaia; Rebekah Barr; Xuechun Zhang; Godwin C G Pais; Christophe Marchand; Yves Pommier; Terrence R Burke; Vinay K Pathak
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue.

Authors:  Qinxue Hu; Ines Frank; Vennansha Williams; John J Santos; Patricia Watts; George E Griffin; John P Moore; Melissa Pope; Robin J Shattock
Journal:  J Exp Med       Date:  2004-04-12       Impact factor: 14.307

View more
  15 in total

Review 1.  Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections.

Authors:  Betsy C Herold; Pedro M Mesquita; Rebecca P Madan; Marla J Keller
Journal:  Am J Reprod Immunol       Date:  2010-12-12       Impact factor: 3.886

2.  Vaginal langerhans cells nonproductively transporting HIV-1 mediate infection of T cells.

Authors:  Lamar Ballweber; Barry Robinson; Allison Kreger; Michael Fialkow; Gretchen Lentz; M Juliana McElrath; Florian Hladik
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

Review 3.  Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities.

Authors:  Florian Hladik; Gustavo F Doncel
Journal:  Antiviral Res       Date:  2010-12       Impact factor: 5.970

4.  The Promise of Antiretrovirals for HIV Prevention.

Authors:  Charlene Flash; Douglas Krakower; Kenneth H Mayer
Journal:  Curr Infect Dis Rep       Date:  2012-04       Impact factor: 3.725

Review 5.  Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities.

Authors:  Charlene S Dezzutti; Florian Hladik
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

Review 6.  Rectal microbicide development.

Authors:  Ian McGowan; Charlene Dezzutti
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

7.  Structure activity relationship of dendrimer microbicides with dual action antiviral activity.

Authors:  David Tyssen; Scott A Henderson; Adam Johnson; Jasminka Sterjovski; Katie Moore; Jennifer La; Mark Zanin; Secondo Sonza; Peter Karellas; Michael P Giannis; Guy Krippner; Steve Wesselingh; Tom McCarthy; Paul R Gorry; Paul A Ramsland; Richard Cone; Jeremy R A Paull; Gareth R Lewis; Gilda Tachedjian
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

8.  3-hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate against HIV type 1 entry by targeting both viral envelope glycoprotein gp120 and cellular receptor CD4.

Authors:  Minmin Li; Jiangman Duan; Jiayin Qiu; Fei Yu; Xiaoyan Che; Shibo Jiang; Lin Li
Journal:  AIDS Res Hum Retroviruses       Date:  2013-06-18       Impact factor: 2.205

9.  Stability and transport of cervical cytobrushes for isolation of mononuclear cells from the female genital tract.

Authors:  Lenine J Liebenberg; Hoyam Gamieldien; Nonhlanhla N Mkhize; Shameem Z Jaumdally; Pam P Gumbi; Lynette Denny; Jo-Ann S Passmore
Journal:  J Immunol Methods       Date:  2011-02-12       Impact factor: 2.303

10.  Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1.

Authors:  Vanessa Pirrone; Shendra Passic; Brian Wigdahl; Fred C Krebs
Journal:  Virol J       Date:  2012-01-26       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.